Calliditas Therapeutics AB (publ) Stock Forecast, Price & News

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Frequently Asked Questions

Is Calliditas Therapeutics AB (publ) a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Calliditas Therapeutics AB (publ) stock.
View analyst ratings for Calliditas Therapeutics AB (publ) or view top-rated stocks.

Are investors shorting Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) saw a increase in short interest in January. As of January 15th, there was short interest totaling 88,900 shares, an increase of 51.2% from the December 31st total of 58,800 shares. Based on an average daily volume of 178,400 shares, the days-to-cover ratio is currently 0.5 days.
View Calliditas Therapeutics AB (publ)'s Short Interest.

When is Calliditas Therapeutics AB (publ)'s next earnings date?

Calliditas Therapeutics AB (publ) is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for Calliditas Therapeutics AB (publ).

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) posted its quarterly earnings data on Wednesday, November, 17th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.62. The company earned $22.92 million during the quarter. During the same period last year, the business posted ($0.62) EPS.
View Calliditas Therapeutics AB (publ)'s earnings history.

What price target have analysts set for CALT?

3 analysts have issued 12-month target prices for Calliditas Therapeutics AB (publ)'s stock. Their forecasts range from $62.00 to $62.00. On average, they expect Calliditas Therapeutics AB (publ)'s share price to reach $62.00 in the next year. This suggests a possible upside of 213.9% from the stock's current price.
View analysts' price targets for Calliditas Therapeutics AB (publ) or view top-rated stocks among Wall Street analysts.

Who are Calliditas Therapeutics AB (publ)'s key executives?

Calliditas Therapeutics AB (publ)'s management team includes the following people:

• Ms. Renee Aguiar-Lucander, Chief Exec. Officer (Age 59)
• Mr. Fredrik Johansson, Chief Financial Officer (Age 44)
• Dr. Katayoun Welin-Berger Ph.D., VP of Operations (Age 53)
• Dr. Johan Haggblad, Chief Scientific Officer (Age 63)
• Mr. Mikael Widell, Head of Communications & IR (Age 63)
• Mr. Jonathan A. Schur, Group Gen. Counsel
• Ms. Ann-Kristin Myde, Head of Clinical Devel. & VP of Project Management (Age 66)
• Mr. Andrew B. Udell B.Sc., M.B.A., Pres of North America (Age 51)
• Dr. Krassimir Mitchev, Head of Medical Affairs (Age 62)
• Dr. Richard S. Philipson M.D., Chief Medical Officer (Age 56)

Who are some of Calliditas Therapeutics AB (publ)'s key competitors?

Some companies that are related to Calliditas Therapeutics AB (publ) include EQRx (EQRX), Corcept Therapeutics (CORT), Aurinia Pharmaceuticals (AUPH), OPKO Health (OPK), Harmony Biosciences (HRMY), Nektar Therapeutics (NKTR), Ligand Pharmaceuticals (LGND), Xencor (XNCR), Schrödinger (SDGR), Mawson Infrastructure Group (WIZP), Taro Pharmaceutical Industries (TARO), Ironwood Pharmaceuticals (IRWD), Global Blood Therapeutics (GBT), ChemoCentryx (CCXI) and I-Mab (IMAB).
View all of CALT's competitors.

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC), DRDGOLD (DRD), (EQX) and Forte Biosciences (FBRX).

When did Calliditas Therapeutics AB (publ) IPO?

(CALT) raised $179 million in an initial public offering on Friday, June 5th 2020. The company issued 9,200,000 shares at $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager.

What is Calliditas Therapeutics AB (publ)'s stock symbol?

Calliditas Therapeutics AB (publ) trades on the NASDAQ under the ticker symbol "CALT."

Who are Calliditas Therapeutics AB (publ)'s major shareholders?

Calliditas Therapeutics AB (publ)'s stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cutler Group LP (0.00%).

Which institutional investors are buying Calliditas Therapeutics AB (publ) stock?

CALT stock was bought by a variety of institutional investors in the last quarter, including Cutler Group LP.

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calliditas Therapeutics AB (publ)'s stock price today?

One share of CALT stock can currently be purchased for approximately $19.75.

How much money does Calliditas Therapeutics AB (publ) make?

Calliditas Therapeutics AB (publ) has a market capitalization of $516.88 million and generates $90 thousand in revenue each year. The company earns $-47.25 million in net income (profit) each year or ($2.10) on an earnings per share basis.

How many employees does Calliditas Therapeutics AB (publ) have?

Calliditas Therapeutics AB (publ) employs 46 workers across the globe.

What is Calliditas Therapeutics AB (publ)'s official website?

The official website for Calliditas Therapeutics AB (publ) is www.calliditas.se.

Where are Calliditas Therapeutics AB (publ)'s headquarters?

Calliditas Therapeutics AB (publ) is headquartered at KUNGSBRON 1 C8, STOCKHOLM V7, 11122.

How can I contact Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ)'s mailing address is KUNGSBRON 1 C8, STOCKHOLM V7, 11122. The company can be reached via phone at 46-8411-3005 or via email at [email protected].